Rashida Rahman, MD
Nephrology · Manassas, VANPI 1982631115
Payments from drug & device makers
Across 378 payments — averaging $649.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Akebia Therapeutics Inc$140K
- Vertex$95K
- Boehringer Ingelheim International GmbH$6K
- Vifor Pharma, Inc.$559
- AstraZeneca$417
- Novartis$362
- plus $4K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Akebia Therapeutics Inc | 142 | $139,891 |
| Vertex | 1 | $94,911 |
| Boehringer Ingelheim International GmbH | 2 | $5,700 |
| Vifor Pharma, Inc. | 31 | $559 |
| AstraZeneca(2 entities) | 19 | $417 |
| Novartis | 19 | $362 |
| Mallinckrodt Hospital Products Inc. | 11 | $350 |
| OPKO Pharmaceuticals, LLC | 18 | $289 |
| ANI Pharmaceuticals, Inc. | 12 | $286 |
| Bayer | 17 | $274 |
| Ardelyx, Inc. | 12 | $261 |
| Boehringer Ingelheim | 6 | $241 |
| Amgen(2 entities) | 12 | $237 |
| Fresenius USA Marketing, Inc. | 19 | $236 |
| Travere Therapeutics, Inc. | 13 | $214 |
| Aurinia Pharma U.S., Inc. | 8 | $189 |
| Novo Nordisk | 4 | $176 |
| GSK | 6 | $155 |
| Otsuka America Pharmaceutical, Inc. | 6 | $142 |
| Medtronic | 1 | $136 |
| Xeris Pharmaceuticals, Inc. | 3 | $112 |
| Mallinckrodt Enterprises LLC | 3 | $67 |
| Calliditas Therapeutics US Inc. | 3 | $63 |
| Lilly USA, LLC | 2 | $50 |
| Daiichi Sankyo Inc. | 2 | $38 |
| Scpharmaceuticals Inc. | 1 | $33 |
| Genentech USA, Inc. | 1 | $27 |
| Sanofi | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Apellis Pharmaceuticals, Inc. | 1 | $19 |
How this compares
$245,500 in reported general payments places this provider in the 90th percentile of 298 nephrology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Manassas
- Olayiwola AyodejiHampton$7M
- Kiranjit DhillonNorfolk$4.5M
- Gaurav GuptaRichmond$2.1M
- Csaba KovesdySalem$1.5M
- Ramon MendezWoodbridge$1.5M
- Varagur Bala SubramanianAlexandria$957K
- Ahmadshah MirkhelFairfax$902K
- Renuka SothinathanFairfax$617K
- Steven LewinskiChesapeake$512K
- Devasmita DevSalem$494K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.